Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FHIT | P49789 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13800984 | 0.86 | MAPT (0.44) | ALDH1A1HPGDMAPTSMN1; SMN2GAA | |
| SCHEMBL13800905 | 0.83 | LMNA (0.47) | ALDH1A1MAPTSMN1; SMN2GAACYP1A2 | |
| SCHEMBL299130 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPTSMN1; SMN2GAA | |
| SCHEMBL4315953 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPTSMN1; SMN2GAA | |
| SCHEMBL13800973 | 0.81 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2GAACYP1A2 | |
| SCHEMBL12536605 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPTSMN1; SMN2GAA | |
| SCHEMBL368639 | 0.79 | HSD17B10 (0.50) | ALDH1A1HPGDMAPTSMN1; SMN2POLB | |
| SCHEMBL24369643 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HPGDMAPTSMN1; SMN2GAA | |
| SCHEMBL281865 | 0.78 | MAPT (0.43) | ALDH1A1HPGDMAPTSMN1; SMN2GAA | |
| SCHEMBL15945408 | 0.78 | GAA (0.50) | ALDH1A1HPGDMAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024245310-A1 | THIAZOLYL OR THIADIAZOLYL AMIDES DERIVATIVES AND USE THEREOF | NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-12-05 | — | — | WO | disclosed |
| CN-118994142-A | Furanamide compound and application thereof | 浙江大学金华研究院 | 2024-11-22 | — | — | CN | disclosed |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-118084937-A | Bicyclic heteroaromatic ring derivatives | 杏林制药株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-11952387-B2 | Bicyclic heteroaromatic ring derivative | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2024-04-09 | — | — | US | disclosed |
| CN-112752761-B | Bicyclic heteroaromatic ring derivatives | 杏林制药株式会社 | 2024-03-29 | — | — | CN | disclosed |
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-08-31 | — | — | US | disclosed |
| WO-2023152182-A1 | NOVEL COMPOUNDS MODULATING MIR-155 | SAVERNA THERAPEUTICS AG (CH) | 2023-08-17 | — | — | WO | disclosed |
| US-11713313-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713313-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| CN-1910166-A | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| EP-0581502-B1 | Antibiotic carbapenem compounds | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | disclosed |
| US-5527793-A | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1996-06-18 | — | — | US | disclosed |
| EP-0581502-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952387-B2 | Bicyclic heteroaromatic ring derivative | ZC3HAV1, RNASEH1, HAVCR2 | ALDH1A1 1471/4885HPGD 3340/4885MAPT 2437/4885 |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HAVCR2, CYP7A1, CYP26B1 | ALDH1A1 629/4885HPGD 1713/4885MAPT 3644/4885 |
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | BCHE, ACHE, CHAT | ALDH1A1 239/4885HPGD 374/4885MAPT 2056/4885 |
| US-11713313-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | ALDH1A1 882/4885HPGD 570/4885MAPT 4200/4885 |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | ALDH1A1 520/4885HPGD 1486/4885MAPT 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.